Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

bi-sialidase fusion protein E-602

A fusion protein composed of two engineered human sialidase molecules fused to an Fc antibody domain, with potential immunomodulating and antineoplastic activities. Upon administration, bi-sialidase fusion protein E-602 targets and binds to sialoglycans overexpressed on the cell surface of certain tumor cells and immune cells, such as exhausted T cells. This degrades the immunosuppressive sialoglycans and allows for the re-activation of the immune system, thereby inducing an anti-tumor immune response. Sialidase is an enzymatic degrader of immunosuppressive sialoglycans. E-602 is based on the enzyme-antibody glyco-ligand editing (EAGLE) platform. The Fc domain enhances retention in the tumor, half-life and manufacturability.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:EAGLE fusion protein E-602
Code name:E 602
E-602
E602
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search